Biovail presents bullish forecast as generic competition grows

Canada's Biovail offered a bullish assessment of its future prospects to a gathering of analysts yesterday and suggested that the biotech may spin off its legacy products into a separate company or income trust. Those products would include the company's compounds that now face generic competition, which triggers a rapid fall in revenue. Biovail recently slashed its US presence, selling much of it to Kos Pharmaceuticals for $104 million. That deal leaves the company better prepared to develop new products needed to take the place of its older drugs, like Wellbutrin XL, as generic competitors take the field, says Biovail CEO Douglas Squires.

- read this report from the National Post for more

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.